Drug Trial Radar · NCT07676266
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Nov 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai AbelZeta Ltd.
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Conditions
- Multiple Sclerosis (MS)
- Myasthenia Gravis (MG)
- Neuromyelitis Optica Spectrum Disorder
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Immune-Mediated Necrotizing Myopathy
Interventions
CD20/BCMA-directed CAR-T cells Autologous 2nd generationBiological
CD20/BCMA-directed CAR-T cells, single infusion intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Adverse Events [Safety and Tolerability]Time frame: Throughout the first 3 months follow up period completion
- The subsequent recommended dose of C-CAR168 in patients with autoimmune diseases refractory to standard therapyTime frame: Throughout the first 24 months follow up period completion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of Qingdao University
Qingdao, Qindao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.